From the publishers of JADPRO

MPN Resource Center

Advertisement

Pacritinib Pretreatment Demonstrates Intriguing Interim Findings in Myelofibrosis

Last Updated: Monday, October 19, 2020

According to abstract data from the phase 2 HOVON-134 trial, presented during the virtual 2020 European Hematology Association Annual Congress, pretreating primary, post-polycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis patients with pacritinib before allogeneic stem cell transplant was shown to be safe.

 

OncLive
Advertisement
News & Literature Highlights
Advertisement
Advertisement